Ontology highlight
ABSTRACT:
PROVIDER: EGAO00000000212 | EGA |
REPOSITORIES: EGA
Molecular oncology 20160817 9
Patients with metastatic bladder cancer have a median survival of only 13-14 months. Precision medicine using targeted therapy may improve survival. Here we investigated spatial and temporal tumour evolution and tumour heterogeneity in order to evaluate the potential use of targeted treatment of metastatic bladder cancer. We performed a proof-of-concept study by whole exome sequencing of multiple tumour regions (n = 22) from three patients with metastatic bladder cancer. DNA from primary and met ...[more]